This company listing is no longer active
MorphoSys Dividends and Buybacks
Dividend criteria checks 0/6
MorphoSys does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-4.1%
Buyback Yield
| Total Shareholder Yield | -4.1% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
MorphoSys: Hold Rating Until The Novartis Deal Closes
May 01Novartis And MorphoSys Are A Perfect Match
Feb 06MorphoSys: Positive Pelabresib Data Finally Unlocking Upside
Jan 18MorphoSys updates Q2 & FY22 guidance below prior provided levels
Jul 26MorphoSys May Not Recover From Adventurous Constellation Buyout
May 04Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
Jan 28Incyte and MorphoSys presents new three-year data for blood cancer therapy
Jun 04MorphoSys reports Q1 results
May 05MorphoSys AG appoints Sangamo 's Sung Lee as new CFO
Jan 06MorphoSys AG (MOR) Investor Presentation - Slideshow
Dec 08MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation
Nov 22MorphoSys reports Q3 results
Nov 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if MOR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MOR's dividend payments have been increasing.
Dividend Yield vs Market
| MorphoSys Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (MOR) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 1.7% |
| Analyst forecast (MOR) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate MOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MOR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate MOR's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MOR has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/05 19:19 |
| End of Day Share Price | 2024/08/05 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MorphoSys AG is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olav Zilian | Baader Helvea Equity Research |
| Brian Balchin | Barclays |
| Rosie Turner | Barclays |